• Home
  • >
  • Natco Pharma Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/natco-pharma-ltd.png Logo

Natco Pharma Ltd Financial Statement

Natco Pharma Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Dec 2023Sep 2023Jun 2023
Revenue654.8955.21,062.9
Operating Expense387488.2544.6
Net Profit192360.2405.3
Net Profit Margin29.3237.7138.13
Earning Per Share10.7220.1122.43
EBIDTA278.3478.5532.2
Effective Tax Rate15.7216.1216.17

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Natco Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual2,707.11,944.82,052.1
Operating Expenses Annual1,771.51,681.31,445.9
Operating Profit Annual1,040.2362.5709.8
Interest Annual14.517.713.3
Depreciation163.8142.6116.9
Net Profit Annual715.3170440.9
Tax Annual146.632.2137.2

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Natco Pharma Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning111.125.819.8
Cash Flow from Operations849.146.5298.8
Cash Flow from Investing-465.34-107.1
Cash Flow from Financing-36334.8-185.7
Cash Flow at the End131.9111.125.8

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Natco Pharma Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)38.4216.4434.59
PBIT Margin (%)32.379.1128.89
PBT Margin (%)29.88.5426.19
Net PROFIT Margin (%)27.17.8718.72
Return On Networth / Equity (%)15.663.2811.21
Return On Networth /Employed(%)17.73.8213.68
Return On Assets (%)14.93.38.8
Total Debt / Equity(X)0.060.080.07
Asset Turnover Ratio (%)0.550.420.47

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Natco Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual2,426.92,311.82,023.2
Total Current Assets Annual3,000.32,486.72,344.8
Non Current Assets Annual2,657.12,622.42,447.1
Total Shareholders Funds Annual4,873.84,263.64,121.6
Total Assets Annual5,657.45,109.14,791.9

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Natco Pharma Ltd Earning Calls
Dec 2023
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Natco Pharma Ltd has a market capitalization of 10,289.83 Cr. Value Research classifies it as a Large-Cap company.

Yes, Natco Pharma Ltd is debt-free with a debt-to-equity ratio of 0.03.

In FY 2023, Natco Pharma Ltd recorded a total revenue of approximately 2,707.1 Cr marking a significant milestone in the company's financial performance.

Natco Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.2% and 0.1% annually, respectively..

Natco Pharma Ltd's current PE ratio is 14.39.

Natco Pharma Ltd's ROCE averaged 11.9% from the FY ending March 2021 to 2023, with a median of 13.5%. It peaked at 17.4% in March 2023, reflecting strong capital efficiency over the period..

Natco Pharma Ltd's latest EBIT is Rs. 876.4 Cr, surpassing the average EBIT of Rs. 563.07 Cr over the 5 years..